Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 30, 2015 7:26 PM ET


Company Overview of Catalent Pharma Solutions, Inc.

Company Overview

Catalent Pharma Solutions, Inc. provides development solutions and delivery technologies for drugs, biologics, and consumer health products. The company’s Development and Clinical Services segment offers manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also provides analytical chemical and cell-based testing and scientific services; respiratory products formulation and manufacturing; regulatory consulting; and bioanalytical testing for biologic products. Its Oral Technologies segment offers oral delivery technologies, including formulation, development, and manufacturing services for the oral dose forms comprising p...

14 Schoolhouse Road

Somerset, NJ 08873

United States

8,300 Employees





Key Executives for Catalent Pharma Solutions, Inc.

Chief Executive Officer, President and Director
Age: 51
Chief Financial Officer, Principal Accounting Officer and Executive Vice President
Age: 48
Senior Vice President of Global Operations
Age: 53
Group President of Clinical Supply Services
Age: 48
President of Oral Technologies - Modified Release Technology
Age: 49
Compensation as of Fiscal Year 2015.

Catalent Pharma Solutions, Inc. Key Developments

Amarantus Bioscience Holdings, Inc. Announces Manufacturing Agreement with Catalent Pharma Solutions

Amarantus BioScience Holdings, Inc. announced that it has entered into a manufacturing agreement with Catalent Pharma Solutions (CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, for clinical-grade production of MANF (mesencephalic-astrocyte-derived neurotrophic factor). Under the agreement, Catalent will provide all cell line engineering, process development and clinical Good Manufacturing Practices (cGMP) biomanufacturing activities necessary for the rapid development of a high performance cell line expressing MANF protein that will thereafter be advanced into scale up for cGMP production. The project will utilize Catalent's proprietary GPEx technology, which creates high-expression, extremely stable cell lines with speed and efficiency, typically capable of getting drug development projects to clinic in one-third the time of traditional approaches. The advantages of applying GPEx technology span from early feasibility studies, to clinical manufacturing and commercial scale production. MANF is a naturally-occurring protein that reduces and prevents apoptosis (programmed cell death) in response to injury or disease. Amarantus is developing MANF for the treatment of orphan ocular indications, including retinitis pigmentosa (RP), and recently received orphan drug designation for MANF for the treatment of RP in the United States and in Europe. In addition, MANF proteins have demonstrated proof-of-concept in animal pre-clinical models to treat a wide range of conditions including retinal artery occlusion, glaucoma, Parkinson's disease (PD), diabetes and ischemic heart disease, among others. With this announcement, Amarantus is initiating Investigational New Drug enabling (IND-enabling) studies to support a first-in-man clinical study with MANF. The Company has retained regulatory expertise to identify the fastest path to human proof-of-concept data by evaluating well-respected regulatory pathways available worldwide, and will be working judiciously towards this objective. Amarantus is targeting the initiation of first-in-man clinical studies for MANF in 2016.

Catalent Pharma Solutions Expands Manufacturing Facility in Winchester, Kentucky

Catalent Pharma Solutions has expanded its manufacturing facility in Winchester, Kentucky. The expansion has seen the doubling of its footprint to 180,000sq.ft. The expansion features newly installed fluid bed capacity, expanded analytical laboratories, and an advanced, open facility design that provides flexibility in supporting the requirements of new customer programs. The expansion was completed in response to increased customer demand for the manufacture of complex, oral solid formulations.

Biohaven Pharmaceutical Holding Company Limited Enters into Exclusive Formulation Agreement and Global License with Catalent for Lead Product

Portage Biotech Inc. announced that Biohaven Pharmaceutical Holding Company Limited has entered into an exclusive world-wide agreement with Catalent Pharma Solutions to provide Catalent's Zydis® Orally Disintegrating Tablet (ODT) technology for Biohaven's lead drug development candidate, BHV-0223. Catalent's proprietary Zydis® technology is a unique, freeze-dried, oral solid dosage form that disperses instantly in the mouth - no water is required. Catalent has been working with Biohaven over the last six months to optimize Biohaven's formulation of BHV-0223 utilizing Zydis® ODT. Prototype development has been completed and manufacturing of clinical drug supplies is being initiated to support the formal IND filing for BHV-0223 as well as initiation of a pharmacokinetic study.

Similar Private Companies By Industry

Company Name Region
Traditional Medicinals, Inc. United States
Plantaceutica, Inc United States
Polaris Pharmaceuticals, Inc. United States
Vaccinoma United States
Firma Medical, LLC United States

Recent Private Companies Transactions

March 30, 2015
Pharmapak Technologies Pty Ltd
October 2, 2014
Redwood Bioscience, Inc.
September 16, 2014
SIGA Technologies, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Catalent Pharma Solutions, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at